The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 4, 2011, Pages 1994-2005

  Schaumberg, Debra A ^a   Nichols, Jason J ^b   Papas, Eric B ^c   Tong, Louis ^d   Uchino, Miki ^e   Nichols, Kelly K ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c BRIEN HOLDEN VISION INSTITUTE   (Australia)

^d Sin gapore National Eye Center   (Singapore)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; LORATADINE;

AGE DISTRIBUTION; AGING; ARTICLE; BIOMICROSCOPY; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTACT LENS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRY EYE; ENVIRONMENTAL FACTOR; ETHNICITY; EYE DISEASE; HUMAN; MEIBOMIAN GLAND DYSFUNCTION; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PAPILLARY CONJUNCTIVITIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SJOEGREN SYNDROME; SYSTEMIC DISEASE; TEAR FILM; WORKSHOP;

EYELID DISEASES; HUMANS; MEIBOMIAN GLANDS; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 79953759322     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6997e     Document Type: Article

References (120)

1. Tiffany JM. The meibomian lipids of the rabbit, I: overall composition. Exp Eye Res. 1979;29:195-202.
2. McFadden WH, Bradford DC, Eglinton G, Hajlbrahim SK, Nico-laides N. Application of combined liquid chromatography/mass spectrometry (LC/MS): analysis of petroporphyrins and meibo-mian gland waxes. J Chromatogr Sci. 1979;17:518-522.
3. Tiffany JM. Individual variations in human meibomian lipid composition. Exp Eye Res. 1978;27:289-300.
4. Baron C, Blough HA. Composition of the neutral lipids of bovine meilbomian secretions. J Lipid Res. 1976;17:373-376.
5. Andrews JS. The meibomian secretion. Int Ophthalmol Clin. 1973;13:23-28.
6. Brown SI, Dervichian DG. The oils of the meibomian glands: physical and surface characteristics. Arch Ophthalmol. 1969;82:537-540.
7. Parakkal PF, Matoltsy AG. The fine structure of the lipid droplets in the meibomian gland of the mouse. J Ultrastruct Res. 1964; 10:417-421.
8. Linton RG, Curnow DH, Riley WJ. The meibomian glands: an investigation into the secretion and some aspects of physiology. Br J Ophthalmol. 1961;45:718-723.
9. Knapp H. Hypertrophy and degeneration of the meibomian glands, I: subsequent history of the case of adenoma of the meibomian glands, reported at the meeting of this society in 1901. Trans Am Ophthalmol Soc. 1903;10:57-63.
10. Randall BA. Sarcoma of the eyelid, simulating a meibomian cyst. Trans Am Ophthalmol Soc. 1887;4:512-520.
11. Florey ME, McFarlan AM, Mann I. Report of forty-eight cases of marginal blepharitis treated with penicillin. Br J Ophthalmol. 1945;29:333-338.
12. Somerset EJ. The significance of errors of refraction in chronic blepharitis of children. Br J Ophthalmol. 1939;23:205-212.
13. Abu-Saif N. The x-ray treatment of blepharitis. Br J Ophthalmol. 1934;18:589-592.
14. Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980;51:243-251.
15. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease: classification and grading of lid changes. Eye. 1991;5:395-411.
16. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop. (2007). Ocul Surf. 2007;5:75-92.
17. Mathers WD, Daley T, Verdick R. Video imaging of the meibo-mian gland. Arch Ophthalmol. 1994;112:448-449.
18. Hom MM. In-office meibography. Rev Optom. 2002;139:22-23.
19. Nichols JJ, Berntsen DA, Mitchell GL, Nichols KK. An assessment of grading scales for meibography images. Cornea. 2005;24:382-388.
20. Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
21. Oden NL, Lilienfeld DE, Lemp MA, Nelson JD, Ederer F. Sensitivity and specificity of a screening questionnaire for dry eye. Adv Exp Med Biol. 1998;438:807-820.
22. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-621.
23. Schaumberg DA, Gulati A, Mathers WD, et al. Development and validation of a short global dry eye symptom index. Ocul Surf. 2007;5:50-57.
24. Gulati A, Sullivan R, Buring JE, Sullivan DA, Dana R, Schaumberg DA. Validation and repeatability of a short questionnaire for dry eye syndrome. Am J Ophthalmol. 2006;142:125-131.
25. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7:S1-S14.
26. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762-770.
27. Lekhanont K, Rojanaporn D, Chuck RS, Vongthongsri A. Prevalence of dry eye in Bangkok, Thailand. Cornea. 2006;25:1162-1167.
28. Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P, Hsu WM. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology. 2003;110:1096-1101.
29. Uchino M, Dogru M, Yagi Y, et al. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci. 2006;83:797-802.
30. Jie Y, Xu L, Wu YY, Jonas JB. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye (Lond). 2009;23:688-693.
31. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114-1119.
32. Ong BL, Larke JR. Meibomian gland dysfunction: some clinical, biochemical and physical observations. Ophthalmic Physiol Opt. 1990;10:144-148.
33. Marren SE. Contact lens wear, use of eye cosmetics, and meibo-mian gland dysfunction. Optom Vis Sci. 1994;71:60-62.
34. Molinari JF, Stanek S. Meibomian gland status and prevalence of giant papillary conjunctivitis in contact lens wearers. Optometry. 2000;71:459-461.
35. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. Optom Vis Sci. 1990;67:710-712.
36. Arita R, Itoh K, Inoue K, Kuchiba A, Yamaguchi T, Amano S. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology. 2009;116:379-384.
37. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991;10:277-285.
38. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43:170-179.
39. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982;89:1173-1180.
40. Auw-Haedrich C, Reinhard T. Chronic blepharitis: pathogenesis, clinical features, and therapy (in German). Ophthalmologe. 2007; 104:817-826; quiz 827-818.
41. Horwath-Winter J, Berghold A, Schmut O, et al. Evaluation of the clinical course of dry eye syndrome. Arch Ophthalmol. 2003;121:1364-1368.
42. Zhang M, Chen JQ, Liu ZG, et al. Clinical characteristics of patients with dry eye syndrome (in Chinese). Zhonghua Yan Ke Za Zhi. 2003;39:5-9.
43. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology. 1998;105:1485-1488.
44. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol. 1995;113:1266-1270.
45. Ong BL. Relation between contact lens wear and Meibomian gland dysfunction. Optom Vis Sci. 1996;73:208-210.
46. Epidemiology Subcommittee of the International Dry Eye WorkShop. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop. (2007). Ocul Surf. 2007;5:93-107.
47. Gipson IK. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2007;48:4390-4398.
48. Jastaneiah S, Al-Rajhi AA. Association of aniridia and dry eyes. Ophthalmology. 2005;112:1535-1540.
49. McCulley JP, Shine WE. Eyelid disorders: the meibomian gland, blepharitis, and contact lenses. Eye Contact Lens. 2003;29:S93-S95; discussion S115-S118, S192-S194.
50. Czepita D, Kuzna-Grygiel W, Czepita M, Grobelny A. Demodex folliculorum and Demodex brevis as a cause of chronic marginal blepharitis. Ann Acad Med Stetin. 2007;53:63-67; discussion 67.
51. Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. 2007;143:743-749.
52. Kojima T, Dogru M, Matsumoto Y, Goto E, Tsubota K. Tear film and ocular surface abnormalities after eyelid tattooing. Ophthalmic Plast Reconstr Surg. 2005;21:69-71.
53. Gonnering RS, Sonneland PR. Meibomian gland dysfunction in floppy eyelid syndrome. Ophthalmic Plast Reconstr Surg. 1987; 3:99-103.
54. Mathers WD, Billborough M. Meibomian gland function and giant papillary conjunctivitis. Am J Ophthalmol. 1992;114:188-192.
55. Martin NF, Rubinfeld RS, Malley JD, Manzitti V. Giant papillary conjunctivitis and meibomian gland dysfunction blepharitis. CLAO J. 1992;18:165-169.
56. Baden HP, Imber M. Ichthyosis with an unusual constellation of ectodermal dysplasias. Clin Genet. 1989;35:455-461.
57. Farjo AA, Halperin GI, Syed N, Sutphin JE, Wagoner MD. Salz-mann's nodular corneal degeneration clinical characteristics and surgical outcomes. Cornea. 2006;25:11-15.
58. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004;2:149-164.
59. Bron AJ, Yokoi N, Gafney E, Tiffany JM. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7:78-92.
60. McCulley JP. Blepharoconjunctivitis. Int Ophthalmol Clin. 1984; 24:65-77.
61. Basta-Juzbasic A, Subic JS, Ljubojevic S. Demodex folliculorum in development of dermatitis rosaceiformis steroidica and rosacea-related diseases. Clin Dermatol. 2002;20:135-140.
62. Den S, Shimizu K, Ikeda T, Tsubota K, Shimmura S, Shimazaki J. Association between meibomian gland changes and aging, sex, or tear function. Cornea. 2006;25:651-655.
63. Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. Cornea. 1992;11:334-342.
64. Sullivan BD, Evans JE, Dana MR, Sullivan DA. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol. 2006;124:1286-1292.
65. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211-222.
66. Mathers WD, Stovall D, Lane JA, Zimmerman MB, Johnson S. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea. 1998;17:353-358.
67. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olm-sted County, Minnesota. Mayo Clin Proc. 2001;76:593-599.
68. Goto E, Matsumoto Y, Kamoi M, et al. Tear evaporation rates in Sjogren syndrome and non-Sjogren dry eye patients. Am J Oph-thalmol. 2007;144:81-85.
69. Pflugfelder SC, Huang AJ, Feuer W, Chuchovski PT, Pereira IC, Tseng SC. Conjunctival cytologic features of primary Sjogren's syndrome. Ophthalmology. 1990;97:985-991.
70. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009;127:763-768.
71. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003; 136:318-326.
72. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000;85:4874-4882.
73. Sullivan BD, Evans JE, Krenzer KL, Reza Dana M, Sullivan DA. Impact of antiandrogen treatment on the fatty acid profile of neutral lipids in human meibomian gland secretions. J Clin En-docrinol Metab. 2000;85:4866-4873.
74. Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? Cornea. 2003; 22:516-521.
75. Sullivan BD, Evans JE, Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. Arch Ophthalmol. 2002;120:1689-1699.
76. Ena P, Pinna A, Carta F. Discoid lupus erythematosus of the eyelids associated with staphylococcal blepharitis and Meibo-mian gland dysfunction. Clin Exp Dermatol. 2006;31:77-79.
77. Kaercher T. Ocular symptoms and signs in patients with ectoder-mal dysplasia syndromes. Graefes Arch Clin Exp Ophthalmol. 2004;242:495-500.
78. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83:1125-1130.
79. Tamer C, Melek IM, Duman T, Oksuz H. Tear film tests in Parkinson's disease patients. Ophthalmology. 2005;112:1795.
80. Iovine A, Fimiani F, Vassallo P, Alessio M, Magli A. Ocular manifestations in a case of childhood cicatricial pemphigoid. Eur J Ophthalmol. 2008;18:636-638.
81. Yavas GF, Ozturk F, Kusbeci T, et al. Meibomian gland alterations in polycystic ovary syndrome. Curr Eye Res. 2008;33:133-138.
82. Horwath-Winter J, Flogel I, Ramschak-Schwarzer S, Hofer A, Kroisel PM. Psoriasis and hypogonadism in chronic blepharokeratoconjunctiviti: a case report (in German). Ophthalmologe. 2002;99:380-383.
83. Zengin N, Tol H, Balevi S, Gunduz K, Okudan S, Endogru H. Tear film and meibomian gland functions in psoriasis. Acta Ophthal-mol Scand. 1996;74:358-360.
84. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104: 1863-1867.
85. Alvarenga LS, Mannis MJ. Ocular rosacea. Ocul Surf. 2005;3:41-58.
86. Zengin N, Tol H, Gunduz K, Okudan S, Balevi S, Endogru H. Meibomian gland dysfunction and tear film abnormalities in ro-sacea. Cornea. 1995;14:144-146.
87. Zuber TJ. Rosacea. Prim Care. 2000;27:309-318.
88. Zuber TJ. Rosacea: beyond first blush. Hosp Pract (Minneap). 1997;32:188-189.
89. Sullivan DA, Schaumberg DA, Schirra F, et al. Sex, sex steroids and dry eye syndromes. In: Zierhut M, Sullivan DA, eds. Immunology of the Lacrimal Gland. London: Tear Film and Ocular Surface; 2005:161-181.
90. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114:1294-1302.
91. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904-912.
92. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107-126.
93. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991;10:286-290.
94. Caffery BE, Josephson JE. Ocular side effects of isotretinoin therapy. J Am Optom Assoc. 1988;59:221-224.
95. Egger SF, Huber-Spitzy V, Bohler K, et al. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora. Acta Ophthalmol Scand. 1995;73:355-357.
96. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: The Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003;31:229-232.
97. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
98. Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. Ocul Surf. 2005;5:143-154.
99. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22:97-101.
100. Creuzot C, Passemard M, Viau S, et al. Improvement of dry eye symptoms with polyunsaturated fatty acids (in French). J Fr Ophtalmol. 2006;29:868-873.
101. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31:141-146; quiz 170.
102. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-356.
103. Miljanovic B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaum-berg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82:887-893.
104. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea. 2007; 26:260-264.
105. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219-225.
106. Viau S, Maire MA, Pasquis B, et al. Efficacy of a 2-month dietary supplementation with polyunsaturated fatty acids in dry eye induced by scopolamine in a rat model. Graefes Arch Clin Exp Ophthalmol. 2009;247:1039-1050.
107. Erdem U, Ozdegirmenci O, Sobaci E, Sobaci G, Goktolga U, Dagli S. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas. 2007;56:257-262.
108. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286: 2114-2119.
109. Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008;85:668-674.
110. Ousler GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther. 2007;29:611-616.
111. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci. 2000;79:961-970.
112. Yaginuma Y, Yamada H, Nagai H. Study of the relationship between lacrimation and blink in VDT work. Ergonomics. 1990;33: 799-809.
113. Fenga C, Aragona P, Cacciola A, et al. Meibomian gland dysfunction and ocular discomfort in video display terminal workers. Eye. 2008;22:91-95.
114. Henriquez AS, Korb DR. Meibomian glands and contact lens wear. Br J Ophthalmol. 1981;65:108-111.
115. Molinari JF. Meibomian gland status comparison between active duty personnel and US veterans. Mil Med. 2000;165:591-593.
116. Arita R, Itoh K, Inoue K, Kuchiba A, Yamaguchi T, Amano S. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology. 2009;116:379-84.
117. Paugh JR, Knapp LL, Martinson JR, Hom MM. Meibomian therapy in problematic contact lens wear. Optom Vis Sci. 1990;67:803-806.
118. Nichols JJ, Sinnott LT. Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye. Invest Oph-thalmol Vis Sci. 2006;47:1319-1328.
119. Nichols JJ, Ziegler C, Mitchell GL, Nichols KK. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol Vis Sci. 2005;46:1911-1914.
120. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7:S1-S14.